through the Integration of Biosensing and AI
Ultra-Precision Sensing Technology
Model BA200
Designed for non-invasive point-of-care assessment of airway inflammation, this device combines high-sensitivity biosensor technology (0.1 ppb) with full ATS/ERS compliance. It delivers multi-parameter results—FeNO, CaNO, FnNO—in under one minute, while a patented dual-channel design ensures complete protection against cross-contamination.
More
Driven by a passion for innovation and a commitment to excellence, desire to maintain high levels of innovation, knowledge, technical expertise, service.
Committed to providing solutions for respiratory diseases, cardiovascular diseases and metabolic diseases
Become a global provider in comprehensive chronic disease solution for both professional segment and homecare.
Fractional nasal nitric oxide (FnNO) testing measures nitric oxide from the nose and sinuses during nasal breathing. Unlike FeNO, it reflects upper-airway biology. FnNO is non-invasive and changes with disease: often elevated in allergic ...
FeNO testing is highly flow-dependent: exhaled flow rate determines which airway compartment is sampled. The standard 50 mL/s maneuver—a slow, steady exhalation against mild resistance for 6–10 seconds—primarily reflects large-airway b...
Fractional exhaled nitric oxide, or FeNO, has a well-earned reputation in asthma. A patient breathes slowly into a handheld device, and within seconds a number appears in parts per billion—a non-invasive readout of type 2 airway inf...
Please complete the form to contact our team